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Mutations in Leucine-rich repeat kinase 2 (LRRK2) are associated with Parkinson’s
disease (PD) and, as such, LRRK2 is considered a promising therapeutic target for
age-related neurodegeneration. Although the cellular functions of LRRK2 in health and
disease are incompletely understood, robust evidence indicates that PD-associated
mutations alter LRRK2 kinase and GTPase activities with consequent deregulation of
the downstream signaling pathways. We have previously demonstrated that one LRRK2
binding partner is P21 (RAC1) Activated Kinase 6 (PAK6). Here, we interrogate the
PAK6 interactome and find that PAK6 binds a subset of 14-3-3 proteins in a kinase
dependent manner. Furthermore, PAK6 efficiently phosphorylates 14-3-3γ at Ser59 and
this phosphorylation serves as a switch to dissociate the chaperone from client proteins
including LRRK2, a well-established 14-3-3 binding partner. We found that 14-3-3γ
phosphorylated by PAK6 is no longer competent to bind LRRK2 at phospho-Ser935,
causing LRRK2 dephosphorylation. To address whether these interactions are relevant in
a neuronal context, we demonstrate that a constitutively active form of PAK6 rescues the
G2019S LRRK2-associated neurite shortening through phosphorylation of 14-3-3γ. Our
results identify PAK6 as the kinase for 14-3-3γ and reveal a novel regulatory mechanism
of 14-3-3/LRRK2 complex in the brain.
Keywords: PAK6, 14-3-3, LRRK2, Parkinson’s disease, phosphorylation
Abbreviations: LRRK2, Leucine-rich repeat kinase 2; PD, Parkinson’s disease; PAK6, P21 (RAC1) Activated Kinase 6; CRIB,
Cdc42 and Rac-interactive binding; BCR, breakpoint cluster region protein; PKA, protein kinase A; CK1α, casein kinase 1
alpha; IKKs, IκB kinases; PP1, protein phosphatase 1; BRET, bioluminescence resonance energy transfer; DIV, days in vitro;
EDTA, ethylenediaminetetraacetic acid; TEMED,N,N,N′,N′ tetramethylethylenediamine; APS, ammonium persulfate; PVDF,
polyvinylidenedifluoride; CAN, acetonitrile; DTT, dithiothreitol; TBS-T, Tris-buffered saline plus 0.1% Triton; BSA, bovine
serum albumin; PFA, paraformaldehyde; SEM, standard error of the mean; LC-MS/MS, liquid chromatography/tandemmass
spectrometry; DMSO, dimethyl sulfoxide; nTg, non-transgenic.
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INTRODUCTION
P21 activated kinase 6 (PAK6) is a member of the group
II PAK serine/threonine kinases, highly conserved enzymes
containing a kinase domain at the carboxyl-terminus and a
Cdc42 and Rac-interactive binding (CRIB) domain at the amino-
terminus (Kumar et al., 2017). PAKs play a central role in signal
transduction and one of the best-characterized functions of these
kinases is their role in actin cytoskeleton reorganization via the
LIM kinase-cofilin pathway (Kumar et al., 2017). In contrast to
class I PAKs (PAK1-3) which are activated by Rho GTPase (e.g.,
Rac1) binding, class II PAKs (PAK4-6) are relocalized by Rho
GTPases at specific signaling sites and locally activated by binding
with specific partners containing SH3 domains (Ha et al., 2012).
Given the importance of cytoskeletal organization in neuronal
development and function, accumulating studies investigated the
role of PAKs in the nervous system and their implication in
neurodegenerative diseases (Civiero and Greggio, 2017). Pak6
knock-out mice are viable and fertile with no overt neurological
defects, whereas the double Pak5/Pak6 knockout mice exhibit
cognitive and locomotor activity deficits, and cultured neurons
display reduced neurite length and number (Nekrasova et al.,
2008). Although PAK6 is almost exclusively expressed in the
brain, the molecular details of PAK6-mediated pathways in
neuronal cells are largely unexplored.
14-3-3s constitute a family of adaptor proteins participating
in multiple processes within in the cell. Dimeric 14-3-
3s bind to their partners at specific phospho-sites (mainly
phospho-serines) and assist protein localization, activity and
stability (Sluchanko and Gusev, 2017). 14-3-3s are themselves
phosphorylated at multiple sites the main ones being Ser58/59,
Ser184, and Ser/Thr232 (https://www.phosphosite.org; Aitken,
2011), although the upstream kinases are poorly characterized.
The breakpoint cluster region protein (BCR) interacts with at
least five isoforms of 14-3-3 in vivo and phosphorylates 14-3-
3τ on Ser233 and to a lesser extent 14-3-3ζ on Thr233 (Clokie
et al., 2005). Instead, protein kinase A (PKA) phosphorylates
14-3-3ζ at Ser58 and PKA-mediated phosphorylation leads to
modulation of 14-3-3ζ dimerization affecting its interaction with
partner proteins (Gu et al., 2006). Functionally, 14-3-3s intervene
in the regulation of small G-proteins and protein kinases related
to the proper functioning of the cytoskeleton (Sluchanko and
Gusev, 2010). Of note, they have been nominated as group
II PAK interactors and Ser99 phosphorylation within PAK4
generates a binding site for 14-3-3γ that promotes the formation
of a PAK4-LIMK1 complex during cell migration (Bastea et al.,
2013).
Recently, we described a novel role for PAK6 in mammalian
brain. We found that PAK6 kinase activity promotes neurite
outgrowth through interaction with the Parkinson’s disease
(PD)-associated leucine-rich repeat kinase 2 (LRRK2) (Civiero
et al., 2015). LRRK2 belongs to the family of ROCO proteins,
characterized by the presence of the bidomain ROC (Ras
of complex proteins) and COR (c-terminal of ROC; Civiero
et al., 2014). ROC functions as a GTPase and represents a
signaling output, whereas COR operates as a dimerization
device (Guaitoli et al., 2016). Another signaling output in
LRRK2 is a serine-threonine kinase domain, which undergoes
both autophosphorylation and heterologous phosphorylation
(Greggio et al., 2009; Sheng et al., 2012). The majority of
PD-associated mutations increase kinase activity in cells and
in vivo (Sheng et al., 2012; Steger et al., 2016), resulting in
neuronal toxicity and, in the case of the common G2019S
mutation, decreased neurite length and complexity (MacLeod
et al., 2006; Sepulveda et al., 2013; Matikainen-Ankney et al.,
2016). LRRK2 undergoes autophosphorylation in vitro and
in vivo (Greggio et al., 2008; Sheng et al., 2012), and it is
phosphorylated by other kinases, including casein kinase 1
alpha (CK1α), IκB kinases (IKKs), and PKA, within a cluster
of N-terminal serine residues (Ser910, Ser935, Ser955, Ser973)
and at S1444 in the ROC domain (Dzamko et al., 2012; Chia
et al., 2014; Muda et al., 2014). Toll-like receptor agonists
increase LRRK2 phosphorylation at Ser935 (Dzamko et al.,
2012), whilst LRRK2 inhibitors abolish auto- and heterologous
phosphorylation causing LRRK2 relocalization into discrete
intracellular clusters (Dzamko et al., 2010). Phosphorylation
of Ser910, Ser935, Ser955, and Ser973 in the N-terminus
and Ser1444 in the ROC domain promote 14-3-3 binding
to LRRK2, which protects LRRK2 from protein phosphatase
1 (PP1)-dependent dephosphorylation and consequent LRRK2
relocalization (Dzamko et al., 2010; Lobbestael et al., 2013; Muda
et al., 2014). While these residues are not autophosphorylation
sites, their phosphorylation status depend on LRRK2 kinase
inhibitors, suggesting that LRRK2 may control a kinase(s)
or phosphatase(s) regulating its phosphorylation cycle. Thus,
the cellular phosphorylation of LRRK2 seems implicated in
its subcellular localization and activation through binding
with 14-3-3 proteins through a yet unknown regulatory
mechanism.
By investigating the PAK6 interactome, we found that
PAK6 binds and phosphorylates 14-3-3γ at Ser59 in vitro and
in cells. Phosphorylation at this specific site induces 14-3-
3γ monomerization, resulting in decreased affinity for client
proteins. Furthermore, we demonstrate that PAK6-dependent
phosphorylation of 14-3-3γ, an established LRRK2 interactor,
promotes 14-3-3γ/LRRK2 complex dissociation in vitro and in
cells with consequent LRRK2 dephosphorylation at Ser935. In
neurons, PAK6 activation rescues the neurite shortening induced
by the pathogenic G2019S LRRK2 form in a process that is
dependent on phospho-Ser59 of 14-3-3γ. Collectively, our work
uncovers PAK6 as the kinase of 14-3-3γ and discloses a novel
pathway by which this enzyme promotes neurite development in
neuronal cells.
MATERIALS AND METHODS
Animals
C57BL/6 LRRK2 wild-type and (mouse) LRRK2 G2019S
BAC mice were obtained from Jackson Laboratory [B6.Cg-
Tg(Lrrk2∗G2019S)2Yue/J]. Housing and handling of mice
were done incompliance with national guidelines. All animal
procedures were approved by the Ethical Committee of the
University of Padova and the Italian Ministry of Health (license
1041/2016-PR).
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Plasmids
Eukaryotic expression contructs of 3xFlag tagged PAK6 (wild
type, K436M and S531N) and 3xFlag LRRK2 (wild type and
G2019S) were generated as described previously (Civiero et al.,
2015). All seven 14-3-3s isoforms were cloned in pET28a(+)
vector in fusion with an N-terminal His-tag for expression in E.
coli cells by PCR amplification of the sequences frommammalian
expression plasmids kindly provided by Prof. Dario Alessi
(University of Dundee). PAK6 and 14-3-3 mutant variants were
generated using the Quick-Change II site-directed mutagenesis
kit (Stratagene). For bioluminescence resonance energy transfer
(BRET) analysis, pRL-TK plasmid (Promega) and pEYFP-C/N1
(Novagene) were modified with GatewayTM Vector Conversion
System (Invitrogen). LRRK2 and 14–3–3γ coding sequences,
respectively, were subsequently cloned inside these vectors
using LR recombination reaction kit (Invitrogen). pmCherry-
N1 vector (Novagen) was used to transfect neurons and trace
neurites.
Antibodies
For immunoprecipitation the following antibodies were used:
mouse Flag M2 (Sigma, Cat# F1804, 1 µg/mg total proteins).
For immunoblotting analysis the following antibodies were
used: Flag M2, HRP conjugated (Sigma, Cat# F1804, 1:10,000),
rabbit pan-14-3-3 Santa Cruz, Cat# sc-629, 1:1,000), mouse
monoclonal Anti-polyHistidine, HRP conjugated (Sigma,
Cat#A7058, 1:10,000), rabbit phospho-PAK4-5-6 (Sigma,
Cat# SAB4504052, 1:2,000), mouse β-tubulin (Sigma, Cat#
T8328, 1:5,000), rabbit pan phospho-Ser58 14-3-3 (Abcam,
Cat# ab30554, 1:1,000), rabbit 14–3–3γ (ThermoFisher, Cat#
PA5-29690, 1:10,000), rabbit MJFF2 (Epitomics Cat# 3514-
1, 1:100), rabbit phospho-Ser935 (Epitomics Cat# 5099-1,
1:100), mouse GFP (Roche, Cat# 1181460001, 1:1,000). For
immunocytochemistry analysis the following antibodies were
used: rabbit PAK6 (Prestige R© Sigma, Cat# HPA031124, 1:200),
rabbit 14–3–3γ (ThermoFisher, Cat# PA5-29690, 1:200), rabbit
pan phospho-Ser58 14-3-3 (Abcam, Cat# ab30554, 1:200).
Chemicals
The PAK inhibitor, PF-3758309 (Selleckchem), was used for
endogenous PAK inhibition at 10µM for 90min. PhosTag
molecule was produced by MRC PPU Reagents and Services,
University of Dundee. All solvents and chemicals used for LC-
MS/MS analysis were of MS grade (Sigma).
Cell Cultures and Transfection
HEK293T cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum.
HEK293T were transfected with plasmid DNA using
polyethylenimine (Polysciences) according to the manufacturer’s
recommendations.
Neuronal Cultures and Transfection
Cortical neuron cultures were prepared from C57BL/6 and
G2019S LRRK2 BAC mouse pups (P0). Neuronal cultures
were plated and grown on 12mm diameter coverslips (400,000
cells/well) in 12-well plastic tissue culture plates as previously
described (Belluzzi et al., 2016). Neuronal cultures were
transfected with DNA plasmids at 3 days in vitro (DIV) using
Lipofectamine 2000 according to the manufacturer’s protocol
(Thermo Fisher). Neurons were fixed using PFA 4% at DIV7 and
subjected to analysis.
Cell Lysis, Co-immunoprecipitation, and
Western Blotting
Cells were harvested at 48 h post-transfection and lysed in buffer
containing 50mM Tris pH 7.5, 1% Triton X-100, 1mM sodium
orthovanadate, 5mM sodium pyrophosphate, 50mM sodium
fluoride, 0.27M sucrose, 1mM ethylenediaminetetraacetic
acid (EDTA). Lysates were incubated with anti-Flag M2
agarose beads (Sigma) overnight. Immunocomplexes were
washed three times with lysis buffer supplemented with
0.25M NaCl. Immunoprecipitates were resuspended in
sample buffer. Between 15 and 30 µg of protein samples were
resolved on pre-casted 4–20% Tris-glycine polyacrylamide gels
(Biorad) or home-casted Tris-glycine polyacrylamide [stacking
gel: 4% (w/v) acrylamide, 125mM Tris/HCl, pH 6.8, 0.1%
(w/v) SDS, 0.2% (v/v) N,N,N′,N′-tetramethylethylenediamine
(TEMED) and 0.08% (w/v) ammonium persulfate (APS),
separating gel: 7.5 or 13% (w/v) acrylamide, 375mM
Tris/HCl, pH 8.8, 0.1% (w/v) SDS, 0.1% (v/v) TEMED,
and 0.05% (w/v) APS] in SDS/Tris-glycine running buffer.
Precision Plus molecular weight markers (Biorad) were used
for size estimation. Resolved proteins were transferred to
polyvinylidenedifluoride (PVDF) membranes using semi-
dry Biorad transfer machine (Trans-Blot Turbo Transfer
System). The PVDF sheets were blocked in Tris-buffered
saline plus 0.1% Triton (TBS-T) plus 5% nonfat dry milk
for 1 h at 4◦C and then incubated overnight at 4◦C with
antibodies in TBS-T plus 5% non-fat dry milk. The PVDF
membranes were washed in TBS-T (3 × 10min) at room
temperature followed by incubation for 1 h at RT with
horseradish peroxidase-conjugated anti-mouse IgG. Blots
were then washed in TBS-T (4 × 10min) at RT and rinsed
in TBS, and immunoreactive proteins were visualized using
enhanced chemiluminescence plus (ECL+, GE Healthcare, Little
Chalfont, England). Densitometric analysis was carried out using
Image J software.
Pull-Down Assay
His-14-3-3 isoforms were expressed in BL21(DE3) bacterial
cells and purified in batch by IMAC with ProBondTM resin
(Invitrogen). After elution, imidazole was removed and buffer
exchange in PBS with a PD10 desalting column (GE healthcare).
After quantification, 3mM dithiothreitol (DTT) was added for
storage and proteins were quickly frozen and kept at −80◦C.
Instead, Flag-tagged proteins were expressed in and purified from
HEK293T cell lines as previously described (Civiero et al., 2015).
Flag-purified proteins bound to the resin were incubated for
2 h with purified His-14-3-3 isoforms (1µM). For the following
procedure see co-immunoprecipitation and western blotting
section.
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Protein Digestion, Phosphopeptide
Enrichment, and LC-MS/MS Analysis
Gel bands were subjected to in-gel digestion with sequencing-
grade modified trypsin (Promega) as detailed in (Belluzzi
et al., 2016). A similar procedure was used for the digestion
of phosphorylated proteins, but in this case LysC was used
as protease. Briefly, gel bands were cut in small pieces,
dehydrated with acetonitrile (ACN) and dried under vacuum.
Reduction of cysteines was performed with freshly prepared
10mM DTT in 25mM Tris-HCl pH 8.5, at 56◦C and for 1 h.
Alkylation was performed with 55mM iodoacetamide (Sigma)
in 25mM Tris-HCl pH 8.5 for 45min at room temperature
and in the dark. Gel pieces were washed several times with
25mM Tris-HCl pH 8.5 and ACN, dried under vacuum, and
suspended LysC solution (Promega, 12.5 ng/mL in 25mM Tris-
HCl pH 8.5). Digestion was performed overnight at 37◦C.
Peptides were extracted with three changes of 50% ACN/0.1%
formic acid (FA, Fluka). Samples were dried under vacuum
and stored at −20◦C till the phosphopeptide enrichment
procedure was performed. Phosphopeptide enrichment and LC-
MS/MS analysis were performed as detailed in (Belluzzi et al.,
2016). Data were acquired with a LTQ-Orbitrap XL mass
spectrometer (Thermo Fisher Scientific) interfaced to a nano-
HPLC Ultimate 3000 (Dionex—Thermo Fisher Scientific). Raw
data files were analyzed with Proteome Discoverer software
(version 1.4, Thermo Fisher Scientific) connected to a Mascot
Server version 2.2.4 (Matrix Science, UK) against the Uniprot
Human Database (version 2015.04.01, 90411 sequences). Trypsin
or LysC were set as digesting enzymes with up to one missed-
cleavage for protein identification and up to three missed-
cleavages for phosphopeptides identification. Carbamidomethyl
cysteine was set as fixed modification and methionine oxidation
as variable modification in all cases. Phosphorylation of
Ser/Thr/Tyr residues was set as variable modifications when the
phosphopeptide analysis was performed. Peptide and fragment
tolerance were 10 ppm and 0.6 Da, respectively. The algorithm
Percolator was used to calculate False Discovery Rate (FDR) and
PhosphoRS algorithm (Taus et al., 2011) was used to help in the
assignment of the correct phosphorylation sites.
Overlay Assays
To directly assess 14-3-3 interaction with targets, overlay assay
were performed as described in Nichols et al. (2010). Briefly,
immunopurified proteins or brain cell lysates were electroblotted
onto nitrocellulose membranes and blocked with 5% skimmed
milk for 30min. After washing with TBS-T, membranes were
incubated with purified His-14-3-3s diluted to 1µg/ml in 5%
bovine serum albumin (BSA) in TBS-T overnight at 4◦C.
Membranes were subsequently cut to allow incubations with
the different 14–3–3γ forms. Subsequent western blotting and
detection was done in parallel to allow quantitative comparison.
In Vitro Kinase Reactions
Kinase assays were carried out as previously described using
1mM ATP (Civiero et al., 2012). Protein concentrations used are
indicated in Figure legends.
PhosTag Gel
Samples were supplemented with 10mM MnCl2 before loading
gels. Phos-tag Tris-glycine polyacrylamide gel was carried out as
described previously (Steger et al., 2016). Gels for Phos-tag Tris-
glycine polyacrylamide gels consisted of a stacking gel [4% (w/v)
acrylamide, 125mM Tris/HCl, pH 6.8, 0.1% (w/v) SDS, 0.2%
(v/v) TEMED, and 0.08% (w/v) APS] and a separating gel [7.5%
(w/v) acrylamide, 375mM Tris/HCl, pH 8.8, 0.1% (w/v) SDS,
75µMPhos-tag acrylamide, 150µMMnCl2, 0.1% (v/v) TEMED,
and 0.05% (w/v) APS].
Anion Exchange Chromatography
Samples belonging from in vitro kinase reactions and
corresponding to 80 µg of recombinant 14-3-3s were loaded
in a 6ml Resource Q column (Amersham Biosciences) and
eluted at 1 ml/min with a discontinuous NaCl gradient (0-0.35
M/6.5-18.5ml, 0.35-0.4 M/18.5-30.5ml, 0.4-1 M/30.5-33.5ml)
in 20mM Tris pH 8 using an ÄKTA purifier system (GE
Healthcare). Signals were recorded with an UV detector set
at 280 nm. Fractions were collected during each run and the
identity of protein peaks subsequently confirmed by dot blot.
Blue Native Gels
Precast vertical SERVAGelTM N Native gels (SERVA
Electrophoresis) 4–16% were loaded and run according to
manufacturer instructions for Blue Native electrophoresis. For
each sample a total amount of 5 µg of protein was loaded. At the
end, the gel was stained with Coomassie Brillant Blue.
Immunocytochemistry and Confocal
Imaging
Transiently transfected HEK293T or neuronal coverslips coated
with poly-L-lysine were fixed with 4% paraformaldehyde (PFA).
Cells were stained with the appropriate primary antibody and
subsequently with secondary anti-mouse AlexaFluor R© 633-
conjugated (Life technologies, Cat# A-21126), anti-rabbit Alexa R©
568-conjugated (Life technologies, Cat# A-11036) or anti-rabbit
DyLight 405-conjugated AffinityPure (Jackson Immunoresearch
Laboratories Inc, Cat# 111-475-003) antibodies were used at
1:200. Images were acquired using a Leica TCS SP5 confocal
microscope or Leica 5000B fluoresce microscope.
For neurite branching analysis, all the measurements were
performed using NeuronJ as previously described (Civiero et al.,
2015). Neurites and dendritic spines were semi-automatically
traced and quantified in terms of length and number.
BRET
HEK293T cells were transfected with indicated expression
vectors. After 48 h, cells were scraped and transferred into a
white OptiPlate-96 (Perkin Elmer). Luminescent emission was
stimulated by adding 5µM Coelenterazine. After 10min signals
derived from RLuc and YFP were collected with the Victor3
plate reader (Perkin Elmer). BRET was calculated by the ratio
YFP/RLuc, after to obtain net BRET (nBRET) the value of BRET
derived from non trasfected cell was subtracted to the samples
values.
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Statistical Analysis
All quantitative data are expressed as mean ± SEM (standard
error of the mean) and represent at least three independent sets
of experiments. Significance of differences between two groups
was assessed by Student t-test or by one-way ANOVA with
Bonferroni’s post-hoc test and two-way ANOVA with Tukey’s
post-hoc test when more than two groups were compared.
RESULTS
PAK6 Interacts with 14-3-3γ in Its Active
State
To identify novel PAK6 effectors and the impact of PAK6 kinase
activity on its interactome, we performed immunoprecipitation
experiments in HEK293T cells using as bait 3xFlag-PAK6 wild-
type and the active variant S531N. As negative control, we
immunoprecipitated kinase-dead PAK6 K436M. The kinase
activity of these functional mutants was previously characterized
in vitro and in cells by our group and others (Schrantz
et al., 2004; Civiero et al., 2015). After SDS-PAGE separation,
coomassie staining revealed the presence of a doublet around
25 kDa that was differentially enriched across the PAK6
variants, with PAK6 S531N displaying the highest affinity
and no bands visible in the PAK6 K436M immunoprecipitate
(Figure 1A). The identity of the two bands was investigated by
liquid chromatography/tandemmass spectrometry (LC-MS/MS)
analysis, revealing multiple 14-3-3 isoforms [γ gamma, θ theta,
η eta, ε epsilon, β beta, ζ zeta; Figure 1A and Supplemental
File (Datasheet 2)]. Using a pan-14-3-3 antibody we confirmed
that PAK6 binds 14-3-3s and that the binding increases
proportionally with PAK6 kinase activity (Figure 1A). Human
14-3-3s constitute a family of seven highly conserved regulatory
proteins (Berg et al., 2003). To further explore the specificity
of PAK6 binding toward the different 14-3-3 isoforms, 3xFlag-
PAK6 bound to anti-Flag resin was incubated with 6xHis-
14-3-3s purified from E. coli. As shown in Figure 1B, PAK6
pulls down several 14-3-3 isoforms but displays the highest
affinity for 14-3-3γ. Since 14-3-3 binding is a function of PAK6
kinase activity (Figure 1A), we then tested 14-3-3γ binding
to PAK6 wild-type, S531N and K436M using overlay assays
(Figure 1C). The kinase activity of PAK6 functional mutants was
assessed by western blot monitoring the autophosphorylation
site Ser560 (Civiero et al., 2015; Figure 1C). As expected,
PAK6 S531N displays two-folds higher affinity for 14-3-3γ
with respect to wild-type, whereas the inactive mutant does
not bind 14-3-3 (Figures 1C,D). Dimeric 14-3-3 proteins
dock onto pairs of phosphorylated serine/threonine residues
on target proteins (Mackintosh, 2004). PAK6 is predicted
to accommodate four potential 14-3-3 binding sites: Thr99,
Ser113, Ser231, and Ser560 (https://ania-1433.lifesci.dundee.
ac.uk/prediction/webserver/index.py/getting_started). Three of
them (Thr99, Ser113, and Ser560) have been previously
found phosphorylated in cells (http://www.phosphosite.org;
Figure 1E). Among them, Thr99 is not involved in 14-3-
3 binding (Tinti et al., 2014). Ser560 is a highly conserved
autophosphorylation site in cells, and it is essential for PAK6
autophosphorylation activity and phosphorylation of substrates
[Kaur et al., 2005; Supplemental File (Datasheet 1): Figures
S1A,B]. Conversely, we found that autophosphorylation of
Ser113 is not required for phosphorylation of PAK6 substrates
but the∼2-fold decrease in 33P incorporation by PAK6 indicates
that it is a bona fide autophosphorylation site [Supplemental File
(Datasheet 1): Figures S1A,B]. Overlay assays with the phospho-
deficient Ser560Ala and Ser113Ala variants indicate that both
sites are required for 14-3-3 binding (Figures 1F,G), consistent
with the typical 14-3-3 binding mode where the dimer docks into
two distinct serine/threonine residues within its targets (Tinti
et al., 2014). Collectively, these experiments indicate that 14-3-
3γ is a PAK6 interactor and that the formation of 14-3-3/PAK6
complex is dependent on PAK6 autophosphorylation on Ser113
and Ser560.
PAK6 Phosphorylates a Subset of 14-3-3s
14-3-3s are phosphorylated at multiple sites (https://www.
phosphosite.org). However, little is known about the
physiological significance of this phosphorylation as well as
the identity of the kinases mediating this process. Interestingly,
14-3-3s contain a putative group II PAKs consensus site
around Ser58/59 (II-PAKs consensus: GGRRRRRSWASPGGK
(Rennefahrt et al., 2007); putative consensus in 14-3-3s:
53VGARRSSWRVISSI66). Therefore, to assess whether 14-3-3s
are phosphorylated by PAK6, we performed radioactive kinase
assays in vitro using recombinant 3xFlag-PAK6 wild-type,
K436M and S531N and the seven 14-3-3 isoforms as substrates.
PAK6 could efficiently phosphorylate a subset of 14-3-3s
(including γ, η, and θ; Figures 2A,B) and PAK6 S531N increased
the amount of radiolabelled 14-3-3 by three- to four-folds
compared to wild-type (Figures 2A,B). Being the best PAK6
interactor and preferred substrate among the seven isoforms, we
selected 14-3-3γ for subsequent investigation. First we evaluate
the stoichiometry of PAK6 phosphorylation on 14-3-3γ with
PhosTag gels coupled with immunoblot analysis. We found
that PAK6 completely phosphorylates 14-3-3γ in vitro after
60min incubation under kinase assay conditions (1mM ATP,
1µM PAK6, and 4µM 14-3-3γ), as revealed by the retarded
electrophoretic mobility of phosphorylated 14-3-3γ (Figure 2C).
Moreover, in cation exchange chromatography, phosphorylated
14-3-3γ elutes at higher NaCl concentrations compared to the
non-phosphorylated protein, consistent with an increase of the
overall negative charge due to the phosphate groups (Figure 2D).
Together, these findings indicate PAK6 as a kinase for 14-3-3γ
in vitro.
Ser59 Phosphorylation of 14-3-3γ Causes
Dimer to Monomer Switch and Loss of
Affinity for the Client Proteins
To identify the site(s) phosphorylated by PAK6 on 14-3-
3γ, we used phospho-peptide enrichment coupled with
LC-MS/MS analysis on purified 14-3-3γ phosphorylated by
PAK6 in vitro. Proteins were digested with LysC to obtain
peptides compatible with MS/MS analysis around the predicted
Ser58 phosphorylation. Under these experimental conditions,
we found a number of putative phosphorylated peptides
[Supplemental File (Datasheet 1): Table S1] but only two of them
(143RATVVESSEK152 and 51NVVGARRSSWRVISSIEQK69)
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FIGURE 1 | Autophosphorylated PAK6 binds 14-3-3γ (A) Immunoprecipitated PAK6 wild-type, S531N, and K436M were subjected to SDS-PAGE analysis and bands
differentially enriched across mutants above 25 kDa were subjected to LC-MS/MS analysis. LC-MS/MS revealed that several 14-3-3 isoforms as kinase-dependent
PAK6 interactors and western blot using pan-14-3-3 antibody confirmed the identity of the proteins (* refers to antibody light and heavy chains). (B) Immunopurified
Flag-PAK6 was used to performed pull-down assays with the seven recombinant 14-3-3 isoforms. Bound 14-3-3s were revealed by western blot using anti-His
antibody.(C) Immunopurified PAK6 wild-type, K436M and S531N were loaded on a SDS-PAGE, transferred on nitrocellulose membrane and subjected to overlay
assays using recombinant 14-3-3γ. Anti-Flag and anti-pSer560 antibodies were used to verify PAK6 loading and activation, respectively, and anti-His to quantify
bound 14-3-3. (D) Quantification of bound 14-3-3γ normalized by total PAK6 amount (n = 3 independent experiments, one-way ANOVA followed by Bonferroni’s
(Continued)
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FIGURE 1 | multiple comparison test; *P ≤ 0.05, **P ≤ 0.01). (E) Schematic representation of PAK6 sequence. In red, putative 14-3-3- binding sites and
phosphorylation (P) (https://www.phosphosite.org/). (F) Immunopurified PAK6 wild-type, S113A and S560A were loaded on SDS-PAGE, transferred onto
nitrocellulose membranes and subjected to overlay assays using recombinant 14-3-3γ. Anti-Flag and anti-pSer560 antibodies were used to confirm PAK6 loading and
activation, respectively, and anti-His to quantify bound 14-3-3. (G) Quantification of bound 14-3-3γ normalized by total PAK6 amount (n = 3 independent
experiments, one-way ANOVA followed by Bonferroni’s multiple comparison test; ***P ≤ 0.001).
were consistently recovered across independent MS runs
[Supplemental File (Datasheet 1): Figures S2A,B]. In both
peptides a group II PAK consensus sequence could be identified
(Figure 3A). The peptide 143RATVVESSEK152 was predicted
to be phosphorylated at the threonine residue (Thr145), whilst
the peptide 51NVVGARRSSWRVISSIEQK69 was found to be
phosphorylated at one of the two tandem serine residues in
position 58 or 59. However, the second serine corresponding to
Ser59 in 14-3-3γ is the one predicted to be recognized by class II
PAKs.
Previous work suggested that phosphorylation of 14-3-3ζ at
Ser58 (corresponding to Ser59 in 14-3-3γ induces dimer to
monomer transition; Woodcock et al., 2003; Zhou et al., 2009).
We therefore performed blue native electrophoresis to evaluate
whether PAK6-mediated phosphorylation alters the dimeric
state of 14-3-3γ. In the absence of ATP (but under the same
kinase assay conditions), 14-3-3γ presents an electrophoretic
mobility around the size of the dimer (Figure 3B). Instead,
PAK6-phosphorylated 14-3-3γ separates as a sharp band around
the monomer size (Figure 3B), indicating that PAK6-mediated
phosphorylation on 14-3-3γ may influence its quaternary
structure. The MS results also hints that Ser59 in 14-3-3γ
might be a putative PAK6 phosphorylation site. To further
explore the consequence of PAK6 phosphorylation on 14-3-
3γ dimer/monomer, we generated 14-3-3γ phosphomimetic
mutants corresponding to the two phospho-sites predicted by
the MS analysis by replacing the serine residues with aspartate
(S59D and T145D). To this end, 14-3-3γ wild-type, S59D and
T145D were purified and loaded on blue native gels. This analysis
revealed that the T145D mutant exhibits an electrophoretic
motility similar to that of the wild-type protein, whereas the
S59D proteins separate as a band compatible with the size of
a monomer (Figure 3C). The dimer to monomer transition
was proposed to decrease the affinity of 14-3-3s for their
target proteins (Tzivion et al., 1998; Zhou et al., 2009). We
therefore investigated the consequence of Ser58 phosphorylation
on mouse brain proteome by overlay assays. Total mouse
brain lysates separated by SDS-PAGE and transferred onto
nitrocellulose membranes were probed with 14-3-3γ wild-
type, 14-3-3γ S59D, 14-3-3γ T145D, and p14-3-3 wild-type
(i.e., phosphorylated by PAK6) and processed in parallel to
allow proper comparison. Overlay assays showed that 14-3-
3γ wild-type and 14-3-3γ T145D bind several proteins on the
membrane (Figure 3D). However, the phosphomimetic 14-3-3γ
S58D and p14-3-3γ display a lower affinity for brain proteins
with respect to the wild-type. Collectively, these results indicate
that PAK6 phosphorylates 14-3-3γ in vitro in at least two
sites, but only Ser59 phosphorylation causes a conformational
change that decreases the affinity of 14-3-3γ for binding
partners.
PAK6 Phosphorylates Endogenous 14-3-3γ
at Ser59
In vitro kinase assays and western blot analysis with pan
anti-phospho Ser58 (Ser59 in 14-3-3γ) antibody confirmed
that PAK6 phosphorylates 14-3-3γ at Ser59 [Figure 4A and
Supplemental File (Datasheet 1): Figure S3]. To investigate
whether this phosphorylation is also relevant in the cellular
context, we used immunofluorescence analysis. We observed
that PAK6 phosphorylates 14-3-3γ at this site in cells co-
transfected with YFP-14-3-3γ and Myc-PAK6 wild-type and
PAK6 S531N, with no staining in the presence of PAK6
kinase dead K436M (Figure 4B). Next, we tested whether
phosphorylation also occurs on endogenous proteins. To this
aim, mouse embryonic fibroblasts, which express high levels
of PAK6 and 14-3-3γ, were acutely treated with the potent
PAK inhibitor PF-3758309 or dimethyl sulfoxide (DMSO)
and analyzed with PhosTag gels. As expected, PF-3758309
treatment efficiently inhibited PAK6 autophosphorylation as
indicated by a significant reduction of the upper band that
correspond to pSer560 (Figures 4C,D). Importantly, a parallel
reduction of the band corresponding to 14-3-3γ phosphorylated
at Ser59 was also evident in the presence of PAK6 inhibition
(Figures 4C,E). Taken together, these experiments demonstrate
that endogenous PAK6 phosphorylates endogenous 14-3-3γ
at Ser59.
Phospho-14-3-3γ Loses Affinity for LRRK2
So far our data suggest that phosphorylation of 14-3-3γ at
Ser59 regulates the affinity for its binding partners. Since
14-3-3s are well established and characterized interactors
of the kinase LRRK2, we asked whether PAK6-mediated
phosphorylation of 14-3-3 impacts LRRK2 binding. Using
overlay assays, we first tested whether PAK6 and LRRK2
share common 14-3-3s interactors. We observed that 14-3-3
zeta, gamma and theta display high affinity for both PAK6
and LRRK2 compared to others isoforms [Supplemental
File (Datasheet 1): Figure S4]. Previous studies indicate
that 14-3-3γ is involved in the regulation of cytoskeletal
dynamics (Bastea et al., 2013), a process also linked with
LRRK2-PAK6 pathway (Civiero et al., 2015). In addition,
14-3-3γ was found to be a LRRK2 interactor by other groups
(Li et al., 2011; Muda et al., 2014) and it is the preferential
PAK6 substrate and interactor across the seven isoforms.
Based on this reasoning, we assessed the effect of PAK6-
mediated phosphorylation of 14-3-3γ on LRRK2 binding
with overlay assays. First, 14-3-3γ was incubated with PAK6
S531N in the presence or absence of 1mM ATP as previously
described (Figure 2C) and subsequently applied in parallel
to nitrocellulose membranes containing equal amounts
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FIGURE 2 | 14-3-3γ is a PAK6 substrate. (A) Recombinant His-14-3-3 isoforms were incubated with Flag-PAK6 wild-type, K436M and S531N (4:1 molar ratio) in the
presence of 33P-ATP/Mg2+ for 1 h and subjected to SDS-PAGE, transferred onto nitrocellulose membranes and imaged with a phosphoscreen. Total protein amount
was verified by western blot with anti-Flag and anti-His antibodies. (B) Quantification of incorporated 33P-radioactivity normalized by total 14-3-3 (n = 4 experiments.
Data are presented as mean ± SEM. Two-way ANOVA followed by Tukey’s multiple comparison test (*P ≤ 0.05, **P ≤ 0.01, and ****P ≤ 0.0001 comparison among
14-3-3 isoforms; $$$P ≤ 0.001, comparison between PAK6 WT versus PAK6 S531N). (C) Purified His-14-3-3γ was incubated with Flag-PAK6 S531N (4:1 molar
ratio) in the presence or absence of 1mM ATP and subjected to PhosTag analysis to analyze phosphorylation stoichiometry and SDS-PAGE to verify total protein
amount. Anti-His antibody was used to reveal 14-3-3 in both cases. (D) Cation exchange profiles of 14-3-3γ phosphorylation by PAK6 (back dashed line) and
non-phosphorylated (black solid line) and NaCl gradient in red. On the bottom, dot blot analysis of eluted fractions using anti-His antibody.
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FIGURE 3 | PAK6-mediated phosphorylation at Ser59 regulates 14-3-3γ affinity for target proteins. (A) Schematic of 14-3-3 protein sequence and selected
phospho-sites identified by LC-MS/MS containing a group II PAK consensus sequence. (B) Recombinant His-14-3-3γ was incubated with Flag-PAK6 S531N (4:1
molar ratio) in the presence or in the absence of 1mM ATP and subjected blue native gel separation. (C) Recombinant His-14-3-3 wild-type, S59D and T145D
quaternary structure were investigated by blue native gel electrophoresis. (D) Total brain proteins were separated by SDS-PAGE, transferred onto nitrocellulose
membranes and subjected to overlay assays using recombinant 14-3-3γ wild-type, S59D, T145D, and PAK6-phosphorylated (p14-3-3). Anti-His antibody,
anti-βeta-tubulin and coomassie staining were used to verify bound 14-3-3 and protein loading, respectively. Representative overlay assays and western blots from n
= 3 independent replicates. Experiments were run in two technical replicates per each condition and in parallel to allow for comparison.
of purified LRRK2. We observed a striking reduction of
phospho-14-3-3γ affinity for LRRK2 compared to non-
phosphorylated proteins, suggesting that phosphorylation may
regulate 14-3-3:LRRK2 complex formation (Figures 5A,B). To
substantiate this finding, we generated alanine mutants of the
two candidate phospho-residues identified by LC-MS/MS (S59A
and T145A) and subjected them to PAK6 phosphorylation in
the presence of 1mM ATP or without nucleotide as control.
We observed that pre-phosphorylation of 14-3-3 reduces
its interaction LRRK2 in wild-type and T145A proteins
but has no effect in the S59A variant (Figures 5C,D). As a
further evidence, the phosphomimetic S59D mutant exhibits
∼80% reduced binding capacity toward LRRK2 compared
to wild-type and T145D 14-3-3γ, phenocopying the effect of
PAK6 phosphorylation (Figure 5E,F). Taken together, these
experiments reveal that PAK6-dependent phosphorylation
of 14-3-3γ at S59 disrupts 14-3-3:LRRK2 complex
in vitro.
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FIGURE 4 | PAK6 phosphorylates 14-3-3γ at Ser59 in cells. (A) Recombinant His-14-3-3γ was incubated with Flag-PAK6 S531N (4:1 molar ratio) in the presence or
absence of 1mM ATP and subjected to western blot analysis. Anti-pSer59 was used to reveal the amount of phosphorylated 14-3-3 and anti-His and anti-Flag
antibodies to verify 14-3-3 and total PAK6 amount. (*) indicates endogenous pSer58/59 revealed by the pan phospho-antibody corresponding to 14-3-3s
co-precipitated with purified PAK6 (see Figure 1A). (B) HEK293T cells co-transfected with YFP-14-3-3γ (green) together and Flag-PAK6 wild-type, K436M, and
S531N. Anti-pSer58 antibody (red) and anti-Flag (cyano) antibodies were used to visualize phosphorylated 14-3-3 and PAK6, respectively. (C) MEF lysates treated
with 10µM PF-3758309 and DMSO as control were loaded in a PhosTag gel. Phospho- and dephospho-proteins (PAK6 and 14-3-3γ) were visualized using
anti-PAK6 or anti-pSer560 antibody and anti-14-3-3γ or anti-pSer58. Protein loading was controlled by western blot using anti-PAK6 and anti-14-3-3γ antibodies.
(D,E) Quantification of pPAK6 normalized by total PAK6 and of p14-3-3γ normalized by total 14-3-3γ. Data are presented as mean ± SEM. **P ≤ 0.01 and ***P ≤
0.001 (n = 3 independent experiments, Student’s t-test).
PAK6 Regulates LRRK2-14-3-3 Binding in
Cells with Consequent Modulation of
LRRK2 Phosphorylation at Ser935
To translate these findings to a cellular context, we employed
BRET to monitor LRRK2/14-3-3γ interaction in the presence
or absence of PAK6. To this end, Renilla luciferase-LRRK2
(Rluc-LRRK2) was used as energy donor and YFP-14-3-
3γ as energy acceptor (Figure 6A). Coelenterazine was the
substrate for the luciferase. Coexpression of Rluc-LRRK2
with YFP-14-3-3γ generated a significant increase in the total
BRET signal compared to YFP alone, with YFP emission
only occurring when in close proximity (<100 Å) to the
luminescent Rluc-LRRK2 (Figure 6B). Instead, coexpression
of donor and acceptor proteins with 3xFlag-PAK6 showed
a significant reduction of nBRET signal (Figures 6B,C),
supporting the notion that PAK6 kinase activity disrupts
the LRRK2/14-3-3γ complex. Dissociation of LRRK2/14-3-3
complex in cells results in dephosphorylation of a cluster of
serines located at the N-terminal region of LRRK2 (Dzamko
et al., 2010; Nichols et al., 2010). To test whether PAK6-
mediated 14-3-3γ dissociation from LRRK2 promotes LRRK2
dephosphorylation at these serine residues, we co-expressed
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FIGURE 5 | Phosphorylation of Ser59 is a switch for LRRK2-14-3-3γ dissociation. (A) Immunopurified Flag-LRRK2 was loaded into SDS-PAGE, transferred onto
nitrocellulose membranes and subjected to overlay assays using recombinant 14-3-3γ and PAK6-phosphorylated 14-3-3γ. Anti-Flag and anti-His antibodies were
used to verify LRRK2 loading and bound 14-3-3γ, respectively. SDS-PAGE/transfers were done in the same gel/membrane and membranes were subsequently cut to
allow incubations with the different 14-3-3γ forms. Subsequent western blotting and detection was done in parallel to allow quantitative comparison. (B)
Quantification of bound 14-3-3γ normalized by total LRRK2 amount (n = 3 independent experiments). Data are presented as mean ± SEM. ***P ≤ 0.001 (Student’s
t-test). (C) Immunopurified Flag-LRRK2 was loaded in SDS-PAGE, transferred onto nitrocellulose membranes and subjected to overlay assays using recombinant
14-3-3γ wild-type, S59A and T145A or PAK6-phosphorylated 14-3-3γ wild-type, S59A and T145A. Anti-Flag and anti-His antibodies were used to verify LRRK2
loading and bound 14-3-3γ, respectively. (D) Quantification of bound 14-3-3γ wild-type, S59A and T145A normalized by total LRRK2 amount. Data are presented as
mean ± SEM. ***P ≤ 0.001 (n = 3 independent experiments, two-way ANOVA followed by Tukey’s multiple comparison test). (E) Immunopurified Flag-LRRK2 was
loaded in SDS-PAGE, transferred onto nitrocellulose membranes and subjected to overlay assays using recombinant 14-3-3γ wild-type, S59D and T145D. Anti-Flag
and anti-His antibodies were used to verify LRRK2 loading and bound 14-3-3γ, respectively. (F) Quantification of bound 14-3-3γ wild-type, S59D and T145D
normalized by total LRRK2 amount. Data are presented as mean ± SEM. *P ≤ 0.05 (n = 3 independent experiments, one-way ANOVA followed by Tukey’s multiple
comparison test).
LRRK2 wild-type together with PAK6 wild-type, K436M
or S531N in HEK293T cells. As predicted, PAK6 induces
LRRK2 dephosphorylation at Ser935 in a kinase dependent
manner (Figures 6D,E), with PAK6 wild-type inducing 40%
reduction of Ser935 phosphorylation relative to empty vector
and S531N abolishing Ser935 phosphorylation (Figure 6E).
We then tested whether dephosphorylated LRRK2 by PAK6
loses affinity for 14-3-3. LRRK2 purified from cells expressing
PAK6 S531N or empty vector was subjected to overlay assays
with 14-3-3γ. We observed that PAK6 promotes a complete
dephosphorylation of LRRK2 at Ser935, which is no longer
competent to bind 14-3-3γ (Figures 6F,G). Taken together,
our results demonstrate that PAK6 kinase activity is critical
for the regulation of LRRK2/14-3-3γ complex in cells by
regulating the constitutive phosphorylation of LRRK2 at
Ser935.
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FIGURE 6 | PAK6 causes LRRK2-14-3-3γ dissociation in cells resulting in LRRK2 de-phosphorylation. (A) BRET uses a bioluminescence luciferase (RLuc) to produce
an initial photon emission (488 nm) compatible with the fluorecence acceptor (YFP) (514 nm), upon the addition of RLuc substrates (coelenterazine). The following
constructs were cloned: LRRK2-RLuc (donor) and YFP-14-3-3γ (acceptor). BRET signal was calculated as described in the Materials and Methods section. (B) Cells
were transfected with LRRK2-RLuc, YFP-14-3-3γ and Flag-PAK6. Anti-LRRK2, anti- Flag, anti-GFP and anti-GADPH were used to verify protein amount. (C) nBRET
signals calculated between LRRK2 and 14-3-3γ in the absence and in the presence of Flag-PAK6 overexpression (n = 4 independent experiments, Student’s t-test
analysis; *P ≤ 0.05). (D) HEK293T cells were transfected with Flag-LRRK2 together with Myc-empty vector (EV), Myc-PAK6 wild-type, K436M and S531N and lysates
(Continued)
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FIGURE 6 | loaded in SDS-PAGE and pSer935-LRRK2 analyzed by western blot using anti-Ser935 antibody and anti-Flag and anti-Myc antibodies to verify LRRK2
and PAK6 amount. (E) Quantification of P-Ser935 normalized by total LRRK2 amount. Data are presented as mean ± SEM. ***P ≤ 0.001 (n = 10
independent experiments, one-way ANOVA followed by Bonferroni’s multiple comparison test). (F) Purified Flag-LRRK2 overexpressed in cells together with Myc-EV
or Myc-PAK6 S531N was loaded in SDS-PAGE, transferred onto nitrocellulose membranes and subjected to overlay assay using recombinant 14-3-3γ. Ponceau
staining and anti-His antibodies were used to verify LRRK2 loading and bound 14-3-3γ, respectively. (G) Quantification of bound 14-3-3γ normalized by total LRRK2
amount. Data are presented as mean ± SEM. *P ≤ 0.05 (n = 3 independent experiments, Student’s t-test analysis).
PAK6 Rescues LRRK2 G2019S Neurite
Shortening via Phosphorylation of 14-3-3γ
at Ser59
To explore the functional implication of these findings in a
neuronal context, we asked whether PAK6 phosphorylation of
14-3-3γ contributes to the previously established link between
LRRK2 and PAK6 in regulating neurite outgrowth (Civiero et al.,
2015). First, we confirmed that PAK6 phosphorylates 14-3-3γ at
Ser59 in primary neuronal cells. To this end, we co-transfected
YFP-14-3-3γ together with PAK6 S531N in primary neurons at
DIV3 and applied immunocytochemistry analysis at DIV7. We
observed that PAK6 clearly enhances the tone of phosphorylation
of 14-3-3γ at Ser59 in neurons [Supplemental File (Datasheet
1): Figure S5]. We previously established that PAK6 promotes
neurite complexity in a kinase-dependent manner and LRRK2
is required for its function (Civiero et al., 2015). Since the PD-
linked LRRK2-G2019S mutant is associated with shorter neurite
development in culture (MacLeod et al., 2006; Winner et al.,
2011; Sepulveda et al., 2013), we then tested whether active PAK6
rescues the G2019S-associated neurite shortening phenotype in
BAC G2019S mice overexpressing murine LRRK2-G2019S. We
prepared primary cortical neurons from both non-transgenic
(nTg) and BAC-LRRK2-G2019S mice and quantified neuronal
branching at DIV7 as previously described (Civiero et al., 2015).
Similar to previous results, LRRK2-G2019S neurons display a
significant decrease in neurite number and length compared
to nTg and, interestingly, ectopic expression of PAK6 S531N
almost completely rescued the neurite shortening phenotype
(Figures 7A,B). To investigate whether the ability of PAK6
to recover the neurite outgrowth defects of G2019S neurons
was dependent on the presence of “phosphorylatable” 14-3-3γ,
we expressed ectopic YFP-14-3-3γ wild-type and YFP-14-3-3γ
S59A in the presence of PAK6 in BAC G2019S neurons. We
observed that PAK6-mediated rescue occurs only in the presence
of wild-type 14-3-3γ but not when phospho-deficient 14-3-3γ
was present (Figures 7C,D). In summary, these experiments
provide evidence that PAK6 phosphorylates 14-3-3γ in neurons
at Ser59 and rescues the PD-linked G2019S LRRK2 neurite
shortening phenotype through phosphorylation of 14-3-3γ at
Ser59.
DISCUSSION
P21-activated kinases comprise a family of serine-threonine
kinases involved in multiple signal transduction pathways,
the majority of them affecting cytoskeletal dynamics (Civiero
and Greggio, 2017; Kumar et al., 2017). They are divided in
two groups according to their activation mechanism, either
dependent (group I, PAK1-3) or independent (group II, PAK4-
6) of small GTPase binding (Kumar et al., 2017). Group II
PAKs are emerging as important players in brain physiology
and pathology, particularly in PD. A constitutively active form
of PAK4 was found to protect the dopaminergic neurons in 6-
hydroxydopamine and α-synuclein rat models of PD (Longo
et al., 2017). In addition, our recent work indicates that the PD-
associated kinase LRRK2 interacts with PAK6 to promote neurite
outgrowth and PD brains show increased PAK6 phosphorylation
(Civiero et al., 2015). In the attempt of identifying novel PAK6
effectors relevant for brain pathophysiology, we undertook an
unbiased proteomic approach and found that 14-3-3s are high-
affinity PAK6 interactors. 14-3-3s were previously suggested to
interact with group II PAKs (Tinti et al., 2014), but the functional
significance of this interaction has not been investigated. Here,
we provide substantial evidence that PAK6 engages in a high-
affinity interaction with 14-3-3γ through its autophosphorylation
sites Ser113 and Ser560. The clear link between PAK6 kinase
activity and its affinity for 14-3-3s prompted us to test PAK6
as a direct kinase for 14-3-3s. Using independent techniques,
we found that PAK6 phosphorylates 14-3-3γ within group
II PAK consensus sites (Ser59 and Thr145) in vitro and in
cells. Phosphorylation seems to be the most important way
of regulating 14-3-3s activity, affecting their interaction with
partners or inducing dissociation of 14-3-3 dimers (reviewed in
Aitken, 2011). We showed that PAK6-mediated phosphorylation
at Ser59, but not at Thr145, decreases the affinity of 14-3-3γ
for client proteins in the brain. Similarly, it has been previously
demonstrated that phosphorylation of 14-3-3ζ by PKA at Ser58
(equivalent to Ser59 in 14-3-3γ) interferes with p53 interaction
(Gu et al., 2006). Ser58(59) is located at the dimer interface
and phosphorylation at this site was proposed to interfere with
dimer formation with consequent impact on the binding with
client proteins (Woodcock et al., 2003; Gu et al., 2006). The
same mechanism was reported for phosphorylated 14-3-3ω at
the equivalent residue in plants (Denison et al., 2014). In line
with these studies, our results show a shift of 14-3-3γ toward a
size compatible with that of a monomer in blue native gels upon
PAK6 phosphorylation in vitro or by mimicking phosphorylation
with S59D but not with S145D. By inspecting the 3D structure of
14-3-3γ, the residue Ser58(9) is positioned in the inner interface
of the dimer and therefore it almost inaccessible for modification,
whilst Thr145 is positioned on the protein surface. As proposed
by others, we cannot exclude that a hierarchical phosphorylation
is required (e.g., a first phosphorylation at Thr145might affect the
monomer/dimer equilibrium allowing a second phosphorylation
at Ser59). Interestingly, dimer-incapable 14-3-3 proteins retained
binding capacity and specificity toward some phospho-partners,
and also demonstrated increased chaperone-like activity on
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FIGURE 7 | G2019S LRRK2 neurite shortening is restored by PAK6-mediated 14-3-3γ phosphorylation. (A) Representative images of primary neurons from nTg and
BAC G2019S LRRK2 mice transfected with an empty vector or Flag-PAK6 S531N. GFP was also overexpressed to analyze neuronal branching. (B) Quantification of
neurite length and number using NeuronJ (ImageJ plugin). Data are presented as mean ± SEM. *P ≤ 0.05 and **P ≤ 0.01 (n = 3 independent primary cultures, n =
50–70 neurons traced, two-way ANOVA followed by Tukey’s multiple comparison test). (C) Representative images of primary neurons from nTg and BAC G2019S
LRRK2 mice transfected with an empty vector or Flag-PAK6 S531N together with YFP-114-3-3γ wild-type and S59A. mCherry was also overexpressed to analyze
neuronal branching. (D) Quantification of neurite length and number using NeuronJ (ImageJ plugin). Data are presented as mean ± SEM. *P ≤ 0.05 and **P ≤ 0.01 (n
= 3 independent primary cultures, n = 30–40 neurons traced, two-way ANOVA followed by Tukey’s multiple comparison test).
various substrates (reviewed in Sluchanko and Gusev, 2012).
Therefore, the general decreased affinity of phospho-14-3-3γ
and S59D 14-3-3γ for partners could be due to the insertion
of a negative charge at Ser59. Indeed, Ser58 is located in close
proximity of residues directly involved with phospho-ligand
binding pocket.
As a proof of concept of our findings, we demonstrated
that PAK6-mediated 14-3-3γ phosphorylation at Ser59 decreases
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its affinity in vitro and in cells for its well-known partner
LRRK2. PAK6-induced loss of 14-3-3 binding on LRRK2 results
in LRRK2 dephosphorylation at Ser935, one of the LRRK2
phosphosite protected by the chaperone. Compelling evidence
revealed that the interaction of LRRK2 with 14-3-3 proteins
prevents dephosphorylation of Ser910/Ser935 and stabilizes
LRRK2 structure, possibly by influencing LRRK2 dimerization
(reviewed in Civiero and Greggio, 2017). Moreover, the ability
to interact with 14-3-3 correlates with the pattern of intracellular
LRRK2 distribution (Dzamko et al., 2010). However, upstream
modulators of the LRRK2/14-3-3 complex and the functional
significance of the LRRK2 release have not been identified yet.
In addition to phospho-Ser910/935/955/973 clustered at the N-
terminal of LRR domain, 14-3-3s bind LRRK2 at phospho-
Ser1444 within the ROC-GTPase domain, with 14-3-3γ isoform
displaying the highest affinity (Muda et al., 2014). The ROC
domain is autophosphorylated by the kinase domain of LRRK2
and this modification is believed to regulate its GTPase activity
(Greggio et al., 2009; Gloeckner et al., 2010; Liu et al., 2016).
According to this model, ROC may represent the signaling
output of LRRK2 and modulation of 14-3-3γ binding may be
implicated in controlling LRRK2 cellular cascades. One of best
characterized phenotype caused by mutant LRRK2 in neurons
is a reduction of neurite complexity (MacLeod et al., 2006;
Sepulveda et al., 2013; Matikainen-Ankney et al., 2016), which
may represent an early event before neuronal degeneration and
motor dysfunction observed in some PD-LRRK2 models (Li
et al., 2010; Melrose et al., 2010; Winner et al., 2011; Longo
et al., 2014; Beccano-Kelly et al., 2015; Yue et al., 2015; Adeosun
et al., 2017). Here we used the BAC-mLRRK2G2019S mouse (Li
et al., 2010), which was previously shown to display the neurite
shortening phenotype (Sepulveda et al., 2013) and to show signs
of neurodegeneration in the substantia nigra pars compacta
at 18 months of age (Chen et al., 2017), to investigate the
potential implication of our findings in LRRK2-PD. We found
PAK6 as an upstream modulator of LRRK2/14-3-3 complex
promotes neurite outgrowth by its activity and rescues the
G2019S LRRK2-induced neurite shortening phenotype through
Ser59 phosphorylation of 14-3-3γ. It is well-established that (1)
G2019S LRRK2 displays higher kinase activity in vitro and in
vivo (Greggio et al., 2006; Sheng et al., 2012) and (2) alanine
substitutions at Ser910/935 interfere with 14-3-3 binding and
decrease LRRK2 activity toward substrates in vitro (Ito et al.,
2016). Putting these two observations together, it is possible that
active PAK6 normalizes LRRK2-G2019S activity by modulating
LRRK2-14-3-3 binding. Based on our findings, PAK6 kinase
activity results in LRRK2 Ser935 dephosphorylation similar to
the effect of direct LRRK2 kinase inhibition, providing protection
against G2019S-associated phenotypes. As safety liabilities of
LRRK2 kinase inhibition have been recently reported (Fuji et al.,
2015), identifying alternative targets—such as PAK6—that may
provide a safer approach than direct LRRK2 inhibition, is of great
value for future therapeutic developments.
Both LRRK2 and PAK6 are kinases upstream the regulation
of actin-cytoskeleton dynamics and we previously found that
they cooperate to promote neurite complexity in mammalian
brain via the LIMK1 pathway (Civiero et al., 2015). It has been
proposed that the expression of 14-3-3θ regulates mutant LRRK2
activity and promotes neurite outgrowth (Lavalley et al., 2016).
In addition, Kaplan et al. reported that 14-3-3ζ intervenes in
axon regeneration and induces neurite branching by interacting
with client proteins (Kaplan et al., 2017). Both studies conclude
that the beneficial effect of 14-3-3θ and 14-3-3ζ on neurons
is disrupted by interfering with general binding of 14-3-3s.
These data partially contrast our finding regarding the ability of
PAK6 to release 14-3-3γ from LRRK2 and rescue LRRK2-linked
pathogenic phenotype, suggesting that a fine balance of 14-3-3-
bound and 14-3-3-free targets is probably required to maintain
cellular homeostasis and that different isoforms cover specific
functions in the cell.
Collectively, our study identifies a novel PAK6-mediated
pathway in neurons that involves the phosphorylation of Ser59
in 14-3-3γ and the consequent regulation of LRRK2-14-3-3γ
complex. We have previously published that brains from G2019S
LRRK2 PD patients display increased PAK6 activation (Civiero
et al., 2015). In light of the present findings, we can speculate
that PAK6 is hyperactivated in PD brains as a feedback response
to normalize LRRK2 activity via 14-3-3γ phosphorylation.
Another possibility that deserves future investigations is that
LRRK2 kinase activity directly or indirectly promotes PAK6
autophosphorylation. Of note, an increased trend of phospho-
Ser58 in 14-3-3s was observed in LRRK2 G2019S mouse brains
(Lavalley et al., 2016). However, additional studies are necessary
to establish whether Ser59 phosphorylation of 14-3-3γ (and
possibly of other isoforms) can be envisaged as a valuable marker
and/or therapeutic target in LRRK2 and sporadic PD.
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